98 related articles for article (PubMed ID: 17146155)
1. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Senba H; Kawano M; Kawakami M
J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
[No Abstract] [Full Text] [Related]
2. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.
Ebcioglu Z; Morgan J; Carey C; Capuzzi D
Ann Intern Med; 2003 Nov; 139(9):W80. PubMed ID: 14597479
[No Abstract] [Full Text] [Related]
3. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
Crook MA; Lynas J; Wray R
J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
Olukoga AO
J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008
[No Abstract] [Full Text] [Related]
5. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Smud R; Sermukslis B
Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
[TBL] [Abstract][Full Text] [Related]
6. The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.
Bhargava A; Gleason S; Vaughan AG; Johnson JF; Yarlagadda KV
Int J Clin Pract; 2013 Nov; 67(11):1151-8. PubMed ID: 24165429
[TBL] [Abstract][Full Text] [Related]
7. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
9. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
Oleesky DA; Mir MA
Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
[No Abstract] [Full Text] [Related]
10. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
[No Abstract] [Full Text] [Related]
11. Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.
Leonard CE; Han X; Bilker WB; Flory JH; Brensinger CM; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
Diabetes Res Clin Pract; 2016 May; 115():60-7. PubMed ID: 27242124
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
[No Abstract] [Full Text] [Related]
13. [Overviews of fibrate].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
[No Abstract] [Full Text] [Related]
14. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
15. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
16. Warfarin potentiation with bezafibrate.
Beringer TR
Postgrad Med J; 1997 Oct; 73(864):657-8. PubMed ID: 9497982
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
Crook M; Lynas J; Wray R
J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
[No Abstract] [Full Text] [Related]
18. Leukopenia and thrombocytopenia caused by thiazolidinediones.
Digman C; Klein AK; Pittas AG
Ann Intern Med; 2005 Sep; 143(6):465-6. PubMed ID: 16172449
[No Abstract] [Full Text] [Related]
19. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
